According to a national study released today, moms are feeling overwhelming pressure to overspend on products for their babies even as they significantly cut back in nearly every other area of their lives to cope with these challenging times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54418-kelton-research-mom-study-baby-products-store-brand-infant-formula
Allergan, Inc. (NYSE: AGN), the makers of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced today the launch of the LATISSE® Wishes Challenge campaign. Inspired by the tradition of blowing on an eyelash to make wishes come true, lifestyle designer Kathy Ireland, professional ballroom dancer Chelsie Hightower and style guide Bobbie Thomas will each lead teams of LATISSE® users from across the country who are challenged to raise more than a quarter of a million dollars for the Make-A-Wish Foundation, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® solution is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/latisse/43354/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
The Ad Council is joining the U.S. Department of Agriculture’s Food Safety and Inspection Service, in partnership with the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), to debut their first joint national multimedia public service campaign to help families prevent food poisoning in the home.
The Food Safe Families campaign was announced this morning by USDA Secretary Tom Vilsack and HHS Secretary Kathleen Sebelius in time for the July 4th holiday and the start of summer when foodborne illnesses tend to increase—a time when many families celebrate with food. It’s also a time when foodborne illnesses tend to increase with more outdoor meals, and other factors that increase the risk for disease-causing bacteria in food.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/adcouncil/50582/
Boston Scientific Corporation (NYSE:BSX) announces U.S. Food and Drug Administration (FDA) approval for the PROMUS Element™ Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the Company’s next-generation drug-eluting stent (DES) technology. The PROMUS Element Stent, designed to provide physicians improved DES performance in treating patients with coronary artery disease, is built on an innovative platinum chromium (PtCr) platform with the market-leading everolimus drug. The Company plans to begin marketing the product in the U.S. immediately.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43510-boston-scientific-fda-promus-element-plus-platinum-chromium-stent-system
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
Many cold sore sufferers try to tough out cold sores or try home remedies that can possibly make their cold sore even worse. There\'s a lot to be learned about the pesky cold sore that you may not know. For example, did you know that as temperatures drop and cold-weather-related illnesses rise, the chance of a cold sore being triggered increases? Cold temperatures and illness are just two triggers that can cause cold sore outbreaks. Other triggers include stress, sun exposure, injury to the mouth, and lack of sleep. Stress, which tends to rear its head during the winter months as many people prepare for the holidays, coupled with cold weather can create the perfect storm for a cold sore outbreak as we enter cold and flu season. Find out how FDA-approved Abreva allows you to win a speedy victory against cold sore attacks.
Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are launching the first FDA-approved, Phase I safety study on the use of cord blood stem cells to treat children with sensorineural hearing loss.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53686-cord-blood-childrens-memorial-hermann-fda-approved-stem-cells-hearing-loss
Como preparación para el 4 julio y los meses veraniegos, período en el cual aumentan los casos de intoxicación alimentaria, el Ad Council y el Servicio de Inocuidad e Inspección de los Alimentos del Departamento de Agricultura de los Estados Unidos, en asociación con la Administración de Alimentos y Medicinas de los Estados Unidos (FDA) y los Centros para el Control y la Prevención de Enfermedades (CDC), prosiguen con su campaña de servicio público Familias Preparando Alimentos Adecuadamente a nivel nacional, el primer esfuerzo en multimedios diseñado para aumentar el grado de conciencia sobre los riesgos de las enfermedades transmitidas por los alimentos (o intoxicación alimentaria) en el hogar. Nuevos anuncios de servicio público (PSA), colocados en vallas, marquesinas de autobuses y otras localidades en exteriores a lo largo y ancho del país, están siendo distribuidos a medios informativos de todo el país y el spot televisivo “Chill” (Refrigere) se transmitirá a través de la cadena Checkout TV Network en 600 en tiendas de Walmart a nivel nacional.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56942-ad-council-usda-hhs-food-safe-families-public-service-campaign
